VISTIDE
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VISTIDE by Gilead Sciences is clinical pharmacology pharmacokinetics vistide must be administered with probenecid. Approved for cmv retinitis in patients with acquired immunodeficiency syndrome (aids). First approved in 1996.
Drug data last refreshed 14h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VISTIDE is an intravenous small-molecule antiviral approved by the FDA in 1996 for treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients. The drug mechanism involves nucleotide analog activity targeting viral DNA polymerase. It represents a legacy antiviral product from Gilead Sciences' early portfolio.
LOE Approaching
With LOE approaching and minimal linked job openings, the VISTIDE team is likely a small legacy franchise operating in wind-down mode with limited commercial growth opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY PHARMACOKINETICS VISTIDE must be administered with probenecid. The pharmacokinetics of cidofovir, administered both without and with probenecid, are described below. The pharmacokinetics of cidofovir without probenecid were evaluated in 27 HIV-infected patients with or without…
Worked on VISTIDE at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.